The big biotech worked a deal with Eisai, offering to cover half of the research and development costs of a pair of mid-stage Alzheimer's therapies and adding an unspecified package of milestones and an upfront in exchange for half the potential profits.
Carlsbad, CA's Isis Pharmaceuticals is touting mid-stage results for its in-development spinal muscular atrophy treatment, setting its sights on a Phase III study and sending its shares up about 15%.
Biogen Idec chairman William Young is taking his last lap at the fast-growing Boston biotech. Young plans to step down from the board in May, when he'll be relieved by Stelios Papadopoulos, the cofounder of Exelixis.
Bayer has posted a fresh set of positive data on its hemophilia therapy BAY94-9027. But with a timeline that doesn't anticipate a regulatory filing until next year, at least one prominent analyst says that Biogen Idec still commands a lead in their race to the market.
Isis and partner Biogen Idec have kicked off a Phase II study of a spinal muscular atrophy treatment, part of the pair's $300 million alliance to advance antisense treatments.
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Shares of Sangamo BioSciences picked up steam early this morning with the news that Biogen Idec is anteing up $20 million and promising up to $300 million more in milestones to partner with the biotech on new therapies for two inherited blood disorders.
Sanofi has been slammed against the regulatory wall at the FDA, picking up a stinging rejection of its multiple sclerosis drug Lemtrada with orders to go back to the clinic for a major round of new trial work if the company ever expects to get the drug over the U.S. finish line at some point.
Biogen Idec is taking its supporting role in a big biosimilars development venture with Korea's Samsung one giant leap forward. The Big Biotech spread the word this morning that it will take the lead on commercializing their anti-TNF knockoffs for some big inflammatory targets--including rheumatoid arthritis and Crohn's disease--in Europe, where they plan to follow a regulatory trail that's already been clearly marked out.
Biogen Idec is sticking close to its research home in Cambridge, MA, in its latest neurodegenerative drug development pact. The big biotech is teaming up with the neighboring Proteostasis Therapeutics on a potential new approach for attacking toxic proteins implicated in the development of Alzheimer's and Parkinson's diseases.